Dr. William Williams reports

BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING

Briacell Therapeutics Corp. has closed its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4 per share. The company received gross proceeds from the offering, before deducting the placement agents' fees and other offering expenses, of $3.05-million. The company relied upon the exemption set forth in Section 602.1 of the Toronto Stock Exchange company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Stock Market.

The company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes and the advancement of business objectives.

ThinkEquity acted as sole placement agent for the offering.

The securities were offered and sold pursuant to the company's effective shelf registration statement on Form S-3 (file No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (SEC) on Jan. 22, 2024, and declared effective on Jan. 31, 2024. The offering was made by means of a prospectus supplement and prospectus, which have been filed with the SEC and are available on the SEC's website. You should read the applicable prospectus supplement and prospectus for more complete information about the company and the offering. You may obtain these documents free of charge by visiting the SEC website. Alternatively, you may obtain copies by contacting ThinkEquity, 17 State St., 41st floor, New York, N.Y., 10004.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.